Cargando…

Efficacy of birinapant in combination with carboplatin in targeting platinum-resistant epithelial ovarian cancers

Patients diagnosed with epithelial ovarian cancers (EOCs) often suffer from disease relapse associated with the emergence of resistance to standard platinum-based chemotherapy. Treatment of patients with chemo-resistant disease remains a clinical challenge. One mechanism of chemoresistance includes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Tanya, Neal, Adam, Dibernardo, Gabriella, Raheseparian, Neela, Moatamed, Neda A., Memarzadeh, Sanaz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878637/ https://www.ncbi.nlm.nih.gov/pubmed/35191515 http://dx.doi.org/10.3892/ijo.2022.5325

Ejemplares similares

Exploring the Potential of Drug Response Assays for Precision Medicine in Ovarian Cancer
por: Singh, Tanya, et al.
Publicado: (2020)

RETRACTED ARTICLE: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
por: La, V., et al.
Publicado: (2017)

Retraction Note: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
por: La, V., et al.
Publicado: (2021)

Editorial Expression of Concern: birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
por: La, V., et al.
Publicado: (2018)

Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers
por: Neal, Adam, et al.
Publicado: (2021)

Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design
por: Li, Yan-Ruide, et al.
Publicado: (2023)

A rare case of vulvar extraskeletal myxoid chondrosarcoma: mimics and diagnostic clues
por: Liou, Sofia S., et al.
Publicado: (2021)

Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors
por: Samiei, Alireza, et al.
Publicado: (2022)

Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells
por: Zhu, Xu, et al.
Publicado: (2018)

Expression of Stromal Progesterone Receptor and Differential Methylation Patterns in the Endometrium May Correlate with Response to Progesterone Therapy in Endometrial Complex Atypical Hyperplasia
por: Neal, Adam S., et al.
Publicado: (2020)

The uterine pathological features associated with sentinel lymph node metastasis in endometrial carcinomas
por: Kang, Yuna, et al.
Publicado: (2020)

Targeting triple-negative breast cancers with the Smac-mimetic birinapant
por: Lalaoui, Najoua, et al.
Publicado: (2020)

Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer(,,)
por: Kim, Kenneth H., et al.
Publicado: (2015)

Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer
por: Wang, Huan, et al.
Publicado: (2022)

Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations
por: Colombo, Marika, et al.
Publicado: (2020)

Examining the In Vitro Efficacy of the IAP Antagonist Birinapant as a Single Agent or in Combination With Dacarbazine to Induce Melanoma Cell Death
por: Vetma, Vesna, et al.
Publicado: (2017)

Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells
por: Niu, Jin, et al.
Publicado: (2020)

Androgen receptor and its correlation with estrogen and progesterone receptors, aimed for identification of cases for future anti-androgen therapy in endometrial cancers
por: Moatamed, Neda A., et al.
Publicado: (2023)

A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.
por: Siddiqui, N., et al.
Publicado: (1997)

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
por: Vasey, P A, et al.
Publicado: (2001)

The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo
por: Zhou, Liang, et al.
Publicado: (2019)

Combinatorial Treatment of Birinapant and Zosuquidar Enhances Effective Control of HBV Replication In Vivo
por: Morrish, Emma, et al.
Publicado: (2020)

Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant
por: Fichtner, Michael, et al.
Publicado: (2020)

Retrospective Analysis Of Comparative Outcomes In Recurrent Platinum-Sensitive Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (Lipo-Dox) And Carboplatin Versus Paclitaxel And Carboplatin
por: Weng, Chia-Sui, et al.
Publicado: (2019)

Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates
por: Liao, John B, et al.
Publicado: (2021)

Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer
por: Colombo, Nicoletta, et al.
Publicado: (2019)

A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids
por: Phan, Nhan, et al.
Publicado: (2019)

AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin
por: Badmann, Susann, et al.
Publicado: (2022)

Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
por: Wagner, U, et al.
Publicado: (2012)

Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study
por: Paksoy, Nail, et al.
Publicado: (2022)

Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC
por: Young, Patricia A., et al.
Publicado: (2021)

Multi‐Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells
por: Zhu, Xu, et al.
Publicado: (2018)

Carboplatin sensitivity in epithelial ovarian cancer cell lines: The impact of model systems
por: Patra, Bishnubrata, et al.
Publicado: (2020)

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer
por: Tan, Xiangbin, et al.
Publicado: (2023)

COM33 suppresses carboplatin-induced epithelial-mesenchymal transition via inhibition of Twist1 in ovarian cancer: COM33 sensitizes ovarian cancer to carboplatin
por: Zhou, Zhiyang, et al.
Publicado: (2022)

Advanced seminoma: treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8).
por: Peckham, M. J., et al.
Publicado: (1985)

NCTD promotes Birinapant-mediated anticancer activity in breast cancer cells by downregulation of c-FLIP
por: Zhao, Li, et al.
Publicado: (2017)

cIAP1/2 are involved in the radiosensitizing effect of birinapant on NSCLC cell line in vitro
por: Sun, Hao, et al.
Publicado: (2021)

A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer
por: Glasspool, R M, et al.
Publicado: (2014)

Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer
por: McMeekin, S, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_5og2ndj045nsidsag7ujkdgv4d